Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
Authors
-
Olga S. Levchenkova
Smolensk State Medical University
https://orcid.org/0000-0002-9595-6982
-
Viktoriya V. Vorobieva
Kirov Military Medical Academy
https://orcid.org/0000-0001-6257-7129
-
Vasiliy E. Novikov
Smolensk State Medical University
https://orcid.org/0000-0002-0953-7993
-
Tatiana I. Legonkova
Smolensk State Medical University
https://orcid.org/0000-0001-9401-2579
-
Elena N. Volkova
Voronezh State Medical University named after N.N. Burdenko
https://orcid.org/0000-0001-8979-3454
DOI:
https://doi.org/10.18413/rrpharmacology.9.10011Abstract
Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy in children and prescribed for chronic ITP refractory to first-line therapy.
Standard ITP pharmacotherapy in children: includes prescribing glucocorticoids or intravenous immunoglobulins.
Thrombopoietin receptor agonists: Currently Romiplostim and Eltrombopag are used in the Russian Federation pediatrics. Their pharmacodynamic features in comparison with other drugs used in ITP are presented in the paper. Increased thrombocytopoiesis is the dominant, but not the only component of Romiplostim and Eltrombopag mechanism of action. It is relevant to study their effect on immune tolerance in ITP, which may be associated with a persistent platelet response in some patients after drug discontinuation.
Conclusion: The issue of thrombopoietin receptor agonist efficacy and safety as well as the mode of their use in ITP children treatment continues to be studied. The high cost of drugs continues to be a limiting factor to their earlier prescription. Generic drugs – Romiplostim and Eltrombopag partly solve the problem, promote their earlier prescription in ITP, but require additional study of their bioequivalence and therapeutic equivalence in comparison with the original drugs.
Graphical Abstract
Graphical Abstract
Keywords:
immune thrombocytopenia, thrombopoietin receptor agonists, Romiplostim, EltrombopagReferences
Alhouri N, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Trevisani F (2020) Lusutrombopag is safe and efficacious for treatment of trombocytopenia in patients with and without hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 18: 2600–2608. https://doi.org/1097/01.HS9.0000561072.99657.03
Al-Samkari H, Grace RF, Kuter DJ (2020) The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology 11(1): 1–13. https://doi.org/10.1177/2040620720912992[PubMed] [PMC]
Audia S, Bonnotte B (2021) Emerging therapies in immune thrombocytopenia. Journal of Clinical Medicine 10: 1004. https://doi.org/10.3390/jcm10051004 [PubMed] [PMC]
Avxentyeva MV, Omelyanovsky VV, Gerasimova KV (2013) Economic analysis of romiplostim (nplate) for treatment of adults with chronic immune thrombocytopenia in Russia. Medical Technologies Assessment and Choice [Meditsinskie Tekhnologii. Otsenka i Vybor] 11(1): 14– [in Russian]
Ayad N, Grace RF, Al-Samkari H (2022) Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Pediatric Blood & Cancer 69(3): e29447. https://doi.org/10.1002/pbc.29447 [PubMed]
Bredlau AL, Semple JW, Segel GB (2011) Management of immune thrombocytopenic purpura in children. Pediatric Drugs 13: 213–223. https://doi.org/10.2165/11591640-000000000-00000 [PubMed]
Cheloff AZ, Al-Samkari H (2019) Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. Journal of Blood Medicine 10(1): 313–321. https://doi.org/10.2147/JBM.S191790 [PubMed]
Clinical guidelines – Immune thrombocytopenia – 2021-2022-2023 (10.11.2021) Approved by the Ministry of Health of the Russian Federation 40 p. [in Russian]
Cooper N, Cines BD (2019) The child with immune thrombocytopenia: to treat or not to treat, is that still the question? Haematologica 104(11): 2132–2134. https://doi.org/10.3324/haematol.2019.229179 [PubMed] [PMC]
Cuker A, Lal L, Roy A, Elliott C, Carlyle M, Martin C, Haenig J, Viana R (2022) Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review. Annals of Hematology 101(9): 1915–1924. https://doi.org/10.1007/s00277-022-04888-7 [PubMed]
Dogan EE, Turan Erkek E, Elverdi T, Celik Kamaci S, Ciftci U, Demirel N, Aydin D, Eren R (2022) Eltrombopag in the treatment of immune thrombocytopenia: Two-center experience from Istanbul. Indian Journal of Hematology and Blood Transfusion 38(2): 327–332. https://doi.org/10.1007/s12288-021-01462-5 [PubMed]
Donyush EK, Soboleva VA, Malkova OV (2015) Using Romiplostim in treatment children with immune thrombocytopenic purpura resistant to corticosteroid (CS) therapy. Disease Treatment and Prevention [Lechenie i Profilaktika] 3(15): 33– [in Russian]
Ghanima W, Cooper N, Rodeghiero N, Godeau B, Bussel J (2019) Thrombopoietin receptor agonists: ten years later. Haematologica 104(6): 1112–1123. https://doi.org/10.3324/haematol.2018.212845 [PubMed] [PMC]
Giordano P, Lassandro G, Barone A, Barone A, Cesaro S, Fotzi I, Giona F, Ladogana S, Miano M, Marzollo A, Nardi M, Notarangelo LD, Pession A, Ruggiero A, Russo G, Saracco P, Spinelli M, Tolva A, Tornesello A, Palladino V, Vecchio G (2020) Use of Eltrombopag in children with chronic immune thrombocytopenia (ITP): A real life retrospective multicenter experience of the Italian association of pediatric hematology and oncology (AIEOP). Frontiers in Medicine 7(1): 1–7. https://doi.org/10.3389/fmed.2020.00066 [PubMed] [PMC]
González-López TJ, Provan D (2022) proposal for a new protocol for the management of immune thrombocytopenia (ITP). Advances in Therapy 39(6): 2287–2291. https://doi.org/10.1007/s12325-022-02133-1 [PubMed]
Grainger JD, Kühne T, Hippenmeyer J, Cooper N (2021) Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. Annals of Hematology 100: 2143– https://doi.org/10.1007/s00277-021-04590-0 [PubMed] [PMC]
Gudbrandsdottir S, Leven E, Imahiyerobo A, Lee KS, Bussel J (2020) Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. British Journal of Haematology 189(1): е31–е67. https://doi.org/1111/bjh.16426 [PubMed]
Zhuravleva MV, Bessemeltsev SS, Khimich TV, Gagarina YuV (2022) Comparative pharmacoeconomic analysis of romiplostim and eltrombopag for the chronic idiopathic thrombocytopenic purpura in Russian Federation. Medical Technologies. Assessment and Choice [Meditsinskie Tekhnologii. Otsenka i Vybor] 44(2): 52–61. https://doi.org/10.17116/medtech20224402152 [in Russian]
Kim TO, Despotovic JM (2021) Pediatric immune thrombocytopenia (ITP) treatment. Annals of Blood 6: 4. https://doi.org/10.21037/aob-20-96
Kontievsky IN, Golenkov AK (2019) Efficacy of agonists thrombopoetin receptor: Romiplostim, Eltrombopag in patients with recurrent primary immune thrombocytopenia. The Bulletin of Hematology [Vestnik Gematologii] 15(4): 8– [in Russian]
Krysanov IS, Zyryanov SK, Krysanova VS (2017) Pharmacoeconomic study of the use thrombopoietin receptor agonists in adult patients with chronic idiopathic thrombocytopenic purpura in Russian Federation. Russian Journal of Hematology and Transfusiology [Gematologiya i Transfuziologiya] 62(1): 20–25. https://doi.org/10.18821/0234-5730-2017-62-1-20-25 [in Russian]
Kuter DJ (2022) The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews 53: 100909. https://doi.org/10.1016/j.blre.2021.100909 [PubMed]
Long М, Kalish LA, Neufeld EJ, Grace RF (2012) Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. American Journal of Hematology 87(3): 315–317. https://doi.org/10.1002/ajh.22261 [PubMed] [PMC]
Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, Orvain C, Graveleau J, Lega JC, Ruivard M, Viallard JF, Cheze S, Dossier A, Bonnotte B, Perlat A, Gobert D, Costedoat-Chalumeau N, Jeandel PY, Dernoncourt A, Michel M, Godeau B, Comont T (2022) Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment. American Journal of Hematology 97(1): 10–1 https://doi.org/10.1002/ajh.26378 [PubMed]
Mareddy C, Kalra M, Sachdeva A (2022) Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India. British Journal of Haematology 197(5): 618–626. https://doi.org/10.1111/bjh.18126 [PubMed]
Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, Wu D, Chen G, Tai Y, Xiong J, Zou J, Hu Y (2022) Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study. Annals of Translational Medicine 10(2): 30. https://org/10.21037/atm-21-4361 [PubMed] [PMC]
Melikyan AL, Pustovaya EI, Tsvetaeva NV (2018) National clinical guidelines for the diagnosis and treatment of primary immune thrombocytopenia (idiopathic thrombocytopenic purpura) in adults. Clinical Guidelines. Protocols of Treatment, 67 pp. [in Russian]
Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, Tvedt T, Ebbo M, Terriou L, Bussel JB, Godeau B (2020) Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood 136(26): 3056-3061. https://doi.org/10.1182/blood.2020007594 [PubMed]
Miltiadous O, Hou M, Bussel JB (2020) Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 135(7): 472–490. https://doi.org/10.1182/blood.2020006529 [PubMed] [PMC]
Neunert C, Vesely SK, Terrell DR, Arnold DM, Mithoowani S, Kim T (2019) American Society of Hematology 2019 guideline for immune thrombocytopenia. Blood Advances 3 (23): 3829–3866. https://doi.org/10.1182/bloodadvances.2019000966 [PubMed] [PMC]
Nolla M, Aladjidi N, Leblanc T, Fernandes H, Ducassou S, Fahd M, Barlogis V, Michel M, Blouin P, Jeziorski E, Benadiba J, Pondarre C, Leverger G, Pasquet M (2021) Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children. Blood 137(1): 138–141. https://doi.org/10.1182/blood.2020006807 [PubMed]
Park YH, Kim DY, Kim S, Choi YB, Shin DY, Kim JS, Lee WS, Mun YC, Jang JH, Lee JW, Kook H, on behalf of Korean Aplastic Anemia Working Party (2022) Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Research 57(1): 20– https://doi.org/10.5045/br.2022.2022043 [PubMed] [PMC]
Payandeh M, Karami A, Karami N (2018) Romiplostim: Successful treatment of a pregnant woman with refractory immune thrombocytopenia. Biomedical Research and Therapy 5(8): 2565– https://doi.org/10.15419/bmrat.v5i8.465 [FullText]
Petrov VY (2016) Intravenous immunoglobulins – the drug of choice in treatment of immune thrombocytopenic purpura in children. Рediatrics [Pediatriya] 95(4): 36– [in Russian]
Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, Nichele I, Sbaraglia M, Zoletto S, Scarmozzino F, Bresciani R, d'Amore F, Friziero A, Guzzardo V, Bertozzi I, Famengo B, d’Amore ESG, Sabattini E, Dei Tos AP (2022) Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia. British Journal of Haematology 198(5): 916–922. https://doi.org/10.1111/bjh.18309 [PubMed]
Propaedeutics of childhood diseases textbook (2021), Kildiyarova RR, Makarova VI (Eds) 3rd edition, revised and supplemented by Borodulina TV, Galaktionova MYu, Ermakova MK, Ivanov DO, Kildiyarova RR, Legonkova TI. LLC GEOTAR-Media Publishing Group, 520 pp. https://doi.org/10.33029/9704-6612-4-PDB-2022-1-520. [in Russian]
Provan D, Semple JW (2022) Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 76: 103820. https://doi.org/10.1016/j.ebiom.2022.103820 [PubMed]
Provan D, Newland AC (2022) Investigational drugs for immune thrombocytopenia. Expert Opinion on Investigational Drugs 31(7): 715–727. https://org/10.1080/13543784.2022.2075340 [PubMed]
Reiser M, Josten KM, Dietzfelbinger H, Seesaghur A, Schill M, Hippenmeyer J, Welslau M (2022) Romiplostim for primary immune thrombocytopenia in routine clinical practice: results from a multicentre observational study in Germany. Acta Haematologica 145(4): 394–403. https://org/10.1159/000521689 [PubMed] [PMC]
Rovó A, Cantoni N, Samii K, Rüfer A, Koenen G, Ivic S, Cavanna D, Benz R (2022) Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS One 17(4): e0267342. https://org/10.1371/journal.pone.0267342 [PubMed]
Rumyancev AG, Maschan AA (2015) Federal`ny`e klinicheskie rekomendacii po diagnostike i lecheniyu immunnoj trombocitopenicheskoj purpury` u detej. Nacional`noe obshhestvo detskix gematologov, onkologov. Natsional’nyy Meditsinskiy Issledovatel’skiy Tsentr Detskoy Ghematologii, Onkologii i Immunologii imeni Dmitriya RogachevaMinzdrava Rossii [Federal Clinical Guidelines on Diagnosis and Treatment of Immune Thrombocytopenic Purpura in Children. Federal State Budgetary Institution ”National Association of Pediatric Haematologists and Oncologists, National Medical Research Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev” of the Ministry of Health of the Russian Federation. [in Russian]
Scaramucci L, Giovannini P, Tendas A, Tendas А, Perrotti A, De Fabritiis P (2014) Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfusion 12(1): 605–607. https://org/10.2450/2014.0246-13 [PubMed] [PMC]
Shabanov PD, Vorobieva VV (2020) Klinicheskaya Farmakologiya [Clinical Pharmacology]. Art Express, S-Petersburg, 696 pp. [in Russian]
Shibata S, Misugi T, Nakane T, Hino M, Tachibana (2022) Use of Eltrombopag for the first trimester pregnancy complicated with refractory idiopathic thrombocytopenic purpura: a case report and literature review. Cureus 14(2): e22505. https://doi.org/10.7759/cureus.22505 [PubMed]
Singh A, Uzun G, Bakchoul T (2021) Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. Journal of Clinical Medicine 10: 789. https://org/10.3390/jcm10040789 [PubMed] [PMC]
Solodovnikov AG, Sorokina EYu, Morkovin EI (2020) Thrombopoietin receptor agonists: clinical use and evaluation of treatment efficacy. Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products [Vedomosti Nauchnogo Tsentra Ekspertizy Sredstv Meditsinskogo Primeneniya] 10(4): 236– https://doi.org/10.30895/1991-2919-2020-10-4-236-243 [in Russian]
Solsona M, Berrueco R, Sebastián E, Cervera Á, Sastre A, Astigarraga I, Argilés B, Dasí MÁ, Dapena JL, Monteagudo E (2022) Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible? British Journal of Clinical Pharmacology 88(9): 4220– https://doi.org/10.1111/bcp.15378 [PubMed]
Suntsova EV, Ignatova AA, Pshonkin AV, Serkova IV, Maschan AA, Novichkova GA, Panteleev MA (2017) Dynamics of platelet functional activity and hemostatic status in a child with chronic immune thrombocytopenia on romiplostim treatment. Pediatric Hematology/Oncology and Immunopathology [Voprosy Ghematologii/Onkologii i Immunopatologii v Pediatrii] 16(3): 69– https://doi.org/10.24287/1726-1708-2017-16-3-69-72 [in Russian]
Suntsova EV, ChikvinaII, Sadovskaya MN, Kotskaya NN, Hachatryan LA, Baydildina DD, Kalinina II, Petrova UN, Pshonkin AV, Lutfullin IY, Lemazina EN, Osipova IV, Galeeva AV, Naumova OS, Fisyn IV, Bikova GV, Kazaryan GR, Maschan AA, Novichkova GA (2020) Use of romiplostim for newly diagnosed immune thrombocytopenia in children. Pediatric Hematology/Oncology and Immunopathology [Voprosy Ghematologii/Onkologii i Immunopatologii v Pediatrii] 19(1): 18– https://doi.org/10.24287/1726-1708-2020-19-1-18-26 [in Russian]
Suvajdzic-Vukovic N, Virijevic M, Pravdic Z, Sabljic N, Adzic-Vukicevic T, Mitrovic M (2022) Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges. Blood Coagulation & Fibrinolysis 33(1): 51–55. https://org/10.1097/MBC.0000000000001109[PubMed]
Teekaput C, Nadsasarn A, Tanprawate S, Soontornpun A, Thiankhaw K, Wantaneeyawong C, Teekaput K, Chai-Adisaksopha C (2022) Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review. Annals of Medicine and Surgery 79: 104116. https://org/10.1016/j.amsu.2022.104116 [PubMed] [PMC]
Tjepkema M, Amini S, Schipperus M (2022) Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis. Critical Reviews in Oncology/ Hematology 171: 103581. https://org/10.1016/j.critrevonc.2022.103581 [PubMed]
Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F (2022) Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Annals of Hematology 101(5): 963– https://doi.org/10.1007/s00277-022-04786-y [PubMed] [PMC]
Vishnu P, Aboulafia DM (2016) Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. Journal of Blood Medicine 7: 99– https://doi.org/10.2147/JBM.S80646 [PubMed] [PMC]
Warrier К, Chauhan A (2012) Management of immune thrombocytopenic purpura: An update. The Ochsner Journal 12(3): 221– https://doi.org/10.2165/11591640-000000000-00000 [PMC]
Williams K (2016) Use of intravenous Anti-RhD Immunoglobulin (RhIG) in the treatment of primary immune thrombocytopenia. Clinical Laboratory Science 29(2): 92–97. https://doi.org/10.29074/ascls.29.2.92
Yasser A, Khasahba EO, Shokeir M, Mabood S (2020) Treatment lines of childhood chronic ITP: A retrospective single-center analysis. Pediatric Hematology/Oncology and Immunopathology [Voprosy Ghematologii/Onkologii i Immunopatologii v Pediatrii] 19(3): 26– https://doi.org/10.24287/1726-1708-2020-19-3-26-30 [in Russian]
Yudina NB, Belyanskaya MV, Solovyova MA, Trubnikova GV, Ryabova EA, Ovchinnikova YuS, Orlova EA, Skorobogatova DA, Brezhneva NV, Ryabova SA, Bykova IL, Sargina EV, Shtokalov AA, Stepanova TV, Grebennikova IV (2019) Experience in the treatment of immune thrombocytopenia in the Department of Oncohematology of Voronezh Regional Children’s clinical hospital № 1. The Russian Journal of Pediatric Hematology аnd Oncology [Rossijskij zhurnal detskoj gematologii i onkologii] 1(6): 28–38.https://org/10.21682/2311-1267-2019-6-1-28-38 [in Russian]
Zotova II, Gritsaev SV, Bessmeltsev SS (2017) Primary immune thrombocytopenia. The current understanding of the pathogenesis and treatment. The Bulletin of Hematology [Vestnik Ghematologii] 13(4): 48-63. [in Russian]
Zotova II, Sergeev VG (2018) Pathogenetic justification for the therapy of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Kazan Medical Journal [Kazanskii Meditsinskii Zhurnal] 99(2): 279-286. https://org/10.17816/KMJ2018-279 [in Russian]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Research Results in Pharmacology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Русский
English
